» Articles » PMID: 35887597

Demographic Patterns of MS Patients Using BRISA: An MS-Specific App in Germany

Overview
Journal J Pers Med
Date 2022 Jul 27
PMID 35887597
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Multiple sclerosis (MS) is a chronic, progressive neurological autoimmune disease impacting quality of life. BRISA is an app designed to help MS patients in Germany track their disease course by symptom-monitoring. This study aimed to understand demographic and health-related characteristics of BRISA users.

Methods: Demographic data provided by 2095 users were analyzed to describe characteristics such as sex, age, type of MS, and medication. The distribution of tracked symptoms based on age and time since diagnosis were studied. Furthermore, the covariance of specific symptom pairs was analyzed.

Results: BRISA users are predominantly female and between 26 and 55 years old. Relapsing-remitting MS was the most prevalent form of MS. First-line category 1 drugs were most frequently used, followed by high-efficacy category 3 drugs (e.g., monoclonal antibodies). The relative frequencies of use of category 1 and category 2 drugs (e.g., spingosine-1-phosphate-receptor modulators) significantly altered with time since diagnosis. Fatigue, concentration disorders, tingling, forgetfulness, and pain were the top five symptoms affecting users.

Conclusion: The results highlight the diversity among MS patients and the need for extensive cohort characterization in the real-world scenario. In-depth analysis could help in identifying novel insights that could aid in disease management.

Citing Articles

Data on Ocrelizumab Treatment Collected by MS Patients in Germany Using Brisa App.

Papukchieva S, Kahn M, Eberl M, Friedrich B, Joschko N, Ziemssen T J Pers Med. 2024; 14(4).

PMID: 38673036 PMC: 11051290. DOI: 10.3390/jpm14040409.


Validated, Quantitative, Machine Learning-Generated Neurologic Assessment of Multiple Sclerosis Using a Mobile Application.

Stoll S, Litchman C, Rubin N, Rubin L, Vartanian T Int J MS Care. 2024; 26(2):69-74.

PMID: 38482515 PMC: 10930805. DOI: 10.7224/1537-2073.2023-009.

References
1.
Ghasemi N, Razavi S, Nikzad E . Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell J. 2017; 19(1):1-10. PMC: 5241505. DOI: 10.22074/cellj.2016.4867. View

2.
Mokry C, Warnke C, Gehring K, Hegen H, Salmen A, Kraemer M . Implementation study of the 2021 German guideline for diagnosis and treatment of multiple sclerosis. Mult Scler Relat Disord. 2021; 57:103434. DOI: 10.1016/j.msard.2021.103434. View

3.
Daltrozzo T, Hapfelmeier A, Donnachie E, Schneider A, Hemmer B . A Systematic Assessment of Prevalence, Incidence and Regional Distribution of Multiple Sclerosis in Bavaria From 2006 to 2015. Front Neurol. 2018; 9:871. PMC: 6218432. DOI: 10.3389/fneur.2018.00871. View

4.
Korakas N, Tsolaki M . Cognitive Impairment in Multiple Sclerosis: A Review of Neuropsychological Assessments. Cogn Behav Neurol. 2016; 29(2):55-67. DOI: 10.1097/WNN.0000000000000097. View

5.
Haase R, Voigt I, Scholz M, Schlieter H, Benedict M, Susky M . Profiles of eHealth Adoption in Persons with Multiple Sclerosis and Their Caregivers. Brain Sci. 2021; 11(8). PMC: 8392753. DOI: 10.3390/brainsci11081087. View